INTRODUCTION

Endoscopic ultrasound (EUS)-guided tissue acquisition is widely used for the pathological diagnosis of various lesions, including pancreatic lesions, submucosal lesions, and lymph node lesions. In the past, EUS-fine-needle aspiration (FNA) has been performed, and its main purpose was to diagnose whether a tumor was benign or malignant. However, the diagnostic ability of histology through this method is approximately 70%, and immunostaining is often challenging. Thereafter, a 19-gauge (G) needle and a Tru-Cut needle were used to enable better tissue sampling. However, handling these needles was difficult due to their stiffness. Therefore, further improvements in the biopsy needle became necessary. EUS-fine-needle biopsy (FNB) needles were developed to obtain more tissue, and several FNB needles are now commercially available. An EchoTip ProCore® HD Ultrasound Biopsy Needle (Cook Endoscopy Inc., Limerick, Ireland), which had a side hole with a reverse bevel, was developed. However, previous meta-analyses have shown no differences in the efficiency of tissue acquisition between this FNB needle and the
PATIENTS AND METHODS

We retrospectively analyzed consecutive patients who underwent EUS-FNB at our institution between June 2016 and March 2020. Two types of FNB needles were predominantly used during the study period: (1) A 20 G EchoTip ProCore® HD Ultrasound Biopsy Needle (Cook Endoscopy Inc.), an FNB Menghini (M) needle that has a core trap with a lateral forward bevel (Fig. 1A) and (2) A 22 G Acquire™ Endoscopic Ultrasound Fine-Needle Biopsy (Boston Scientific Corporation), an FNB Fransen (F) needle (Fig. 1B). The following patients were excluded: (1) Those who underwent EUS-FNB for one lesion with several types of needles, and did not receive an individual diagnosis for the samples acquired with each needle, and (2) those who could not be followed up until the final diagnosis.

Procedure

EUS-guided tissue acquisition was performed using a convex linear-array echoendoscope (GF-UCT260; Olympus Medical Systems, Tokyo, Japan) under moderate sedation with midazolam and analgesia with pethidine. The use of each EUS-FNB needle was divided over time: M needle was used between June 2016 and January 2019 and F needle between February 2019 and March 2020. The procedure was performed by experts (≥ 5 years of experience in EUS tissue acquisition) or trainees (< 5 years of experience in EUS tissue acquisition) under the guidance of experts.

The size of the lesion was defined as the maximum diameter visualized on EUS, and the length of the FNB needle passing through the lesion was defined as the puncture length. At the first puncture, a 10 mL syringe suction was applied, and 20 strokes were performed using the fanning technique. When large amounts of blood were suctioned, the operator decided to use the slow pull method for the subsequent session. After each puncture, a rapid on-site evaluation (ROSE) was performed by the cytologist. On confirming that the target tissue was collected for ROSE, the procedure was completed with one additional puncture to obtain a sufficient sample for histological diagnosis, provided the lesion could be safely punctured again. Finally, the obtained specimens were fixed in 7% formalin and processed for histological examination.

Evaluation

This study evaluated the diagnostic yield and the adverse events (AEs) associated with EUS-FNB. The diagnostic yield was evaluated per lesion, while AEs were calculated per patient. When the same needle was used to puncture multiple lesions, each lesion was evaluated individually. If two types of needles were used for one lesion, the diagnostic yield was evaluated for each needle. The tissue acquisition rate was defined as the sum of lesions in which a histological diagnosis could be obtained, divided by the total number of lesions. An accurate diagnosis was defined as a malignant disease being diagnosed as malignant and a benign disease as benign. Diagnostic accuracy was defined as the sum of accurate diagnoses divided by the total number of lesions. AEs were defined as any postprocedural events using a lexicon for endoscopic AEs.

Statistical analysis

Continuous variables were presented as medians (ranges) and compared using the Mann–Whitney U test. Categorical variables were described as absolute numbers (proportions).
and analyzed using the Chi-squared or Fisher’s exact test. A p-value < 0.05 was considered statistically significant. The following five variables were assessed by univariate analysis to identify the influencing factors for obtaining a histological diagnosis: FNB needle (M vs. F), location (pancreas vs. lymph node vs. submucosal tumor vs. others), access route (transgastric vs. transduodenal vs. others), size of lesion (small lesion; ≤ 2 cm vs. large lesion; > 2 cm), and the physician performing the procedure (expert vs trainee). Factors in the univariate analysis with a p-value < 0.15 were subjected to multivariate logistic regression analysis, and odds ratios (ORs) with a 95% confidence interval (CI) were calculated. Propensity score matching in a one-to-one ratio with a caliper width equal to 0.2 was applied to create comparable cohorts between the M and F groups. The propensity score was calculated with factors including the location of the lesion, access route, size of the lesion, puncture length, and number of punctures. All statistical analyses were performed using EZR ver. 1.40 (Saitama Medical Center, Jichi Medical University, Saitama, Japan). The clinical data were followed up until April 2020.

This study was approved by the ethics committee of our institution (approval number: 2019-1191). All procedures were performed in accordance with the Declaration of Helsinki and written informed consent for the procedure was obtained from all patients.

RESULTS

A total of 711 patients underwent EUS-FNB during this period. Out of these, 41 patients had EUS-FNB performed by several types of needles in one session and did not receive individual diagnoses for the samples obtained by each needle. Four patients were lost to follow-up. The above patients were excluded according to the exclusion criteria. Consequently, 666 patients and 690 lesions were analyzed in this study (Fig. 2). The final diagnoses included 614 malignant and 76 benign lesions. Fifteen patients received punctures for two or three lesions, and eight lesions had to be punctured by two FNB needles. M needle could puncture all the lesions successfully, while two lesions (a gastric submucosal tumor and an abdominal lymph node) could not be punctured by F needle (technical success rate; M 100% [409/409] and F 99.3% [279/281] [p = 0.17]).
M needles were used for 409 lesions, and F needles for 281 lesions (Table 1). Pancreatic lesions were the most common (77.2%, 533/690). There was no significant difference in the location of the lesion between the two groups ($p=0.10$). Transgastric access was most frequently used in the M group ($p<0.01$). The median size of the lesion was significantly larger, and the puncture length was significantly longer in the M group (median size: M/F 27/25 mm; $p<0.01$; median puncture length: M/F 21/18 mm; $p<0.01$). There was no significant difference in the number of punctures between the two groups (median of 2 in both groups, $p=0.07$). There was no difference in the proportion of procedures performed by trainees between the two groups ($p=0.11$). The overall tissue acquisition rate was 98.4%, and the diagnostic rates of histology alone and histology with cytology were 88.8% and 95.7%, respectively. The tissue acquisition rates in the M and F groups were 99.8% and 96.4% ($p<0.01$), the diagnostic yields of histology alone in the M and F groups were 90.5% and 86.5% ($p=0.11$), and those of histology combined with cytology were 97.6% and 92.9% ($p<0.01$), respectively.

Ten AEs occurred in total (1.5%; 10/666). Five cases of mild bleeding, one case of mild pancreatitis, and one case of needle fracture occurred in the M group. Two cases of mild bleeding and two of mild pancreatitis occurred in the F group.

Table 1. Characteristic of Study Lesions in Each Needle (n=690)

|                        | Menghini needle (n=409) | Franseen needle (n=281) | $p$-value |
|------------------------|-------------------------|-------------------------|-----------|
| **Location, n (%)**    |                         |                         |           |
| Pancreas               | 305 (74.6%)             | 228 (81.1%)             | 0.10      |
| Head                   | 98 (32.1%)              | 112 (49.1%)             |           |
| Body and tail          | 207 (67.9%)             | 116 (50.9%)             |           |
| Lymph node             | 38 (9.3%)               | 25 (8.9%)               |           |
| Submucosal tumor       | 36 (8.8%)               | 18 (6.4%)               |           |
| Esophagus              | 9 (25.0%)               | 1 (5.6%)                |           |
| Stomach                | 26 (72.2%)              | 17 (94.4%)              |           |
| Duodenum               | 1 (2.8%)                |                         |           |
| Others                 | 30 (7.3%)$^a$           | 10 (3.6%)$^a$           |           |
| **Access route, n (%)**|                         |                         | <0.01     |
| Transgastric           | 275 (67.2%)             | 165 (58.7%)             |           |
| Transduodenal          | 110 (26.9%)             | 107 (38.1%)             |           |
| Others                 | 24 (5.9%)$^a$           | 9 (3.2%)$^a$            |           |
| **Size of lesion (mm), median (range)** | 27 (10–94) | 25 (9–86) | <0.01 |
| **Number of punctures, median (range)** | 2 (1–9) | 2 (1–6) | 0.07 |
| **Puncture length (mm), median (range)** | 21 (9–65) | 18 (5–52) | <0.01 |
| **Experts/trainees, n** | 159/250 | 92/189 | 0.11 |
| **Tissue acquisition rate** | 99.8% | 96.4% | <0.01 |
| **Diagnostic yield**   |                         |                         |           |
| Cytology only          | 91.9%                   | 87.5%                   | 0.07      |
| Histology only         | 90.5%                   | 86.5%                   | 0.11      |
| Histology plus cytology| 97.6%                   | 92.9%                   | <0.01     |

$^a$Including intraperitoneal nodule 12, liver 6, adrenal grand 5, mediastinum 4, and gall bladder 3.

$^b$Including intraperitoneal nodule 8, liver 1, and mediastinum 1.

$^c$Transesophageal 24.

$^d$Transesophageal 4, through the jejunum 3, and through the rectum 2.
Table 2. Factors Influencing Histological Diagnostic Accuracy for Malignancy; Multivariate Analysis

|                  | Univariate          | Multivariate         |
|------------------|---------------------|----------------------|
|                  | OR (95% CI)         | p-value              | OR (95% CI)         | p-value              |
| **FNB needle**   |                     |                      |                     |                      |
| Menghini needle  | 1.48 (0.92–2.39)    | 0.10                 | 1.24 (0.76–2.02)    | 0.40                 |
| Franseen needle  | 1                   |                      | 1                   |                      |
| **Location**     |                     |                      |                     |                      |
| Pancreas         | 1                   |                      |                      |                      |
| Lymph node       | 0.79 (0.37–1.68)    | 0.54                 |                      |                      |
| Submucosal tumor | 2.24 (0.68–7.39)    | 0.19                 |                      |                      |
| Others           | 1.62 (0.49–5.42)    | 0.43                 |                      |                      |
| **Access route** |                     |                      |                     |                      |
| Transgastric     | 1                   |                      | 1                   |                      |
| Transduodenal    | 0.52 (0.32–0.85)    | <0.01                | 0.50 (0.31–0.82)    | <0.01                |
| Others           | 1.55 (0.36–6.72)    | 0.56                 | 1.42 (0.33–6.19)    | 0.64                 |
| **Size of lesion** |                     |                      |                     |                      |
| Small lesion     | 0.53 (0.32–0.86)    | 0.01                 | 0.52 (0.31–0.86)    | 0.01                 |
| Large lesion     | 1                   |                      | 1                   |                      |
| **Physician**    |                     |                      |                     |                      |
| Expert           | 0.83 (0.51–1.35)    | 0.45                 |                      |                      |
| Trainee          | 1                   |                      |                      |                      |

CI, confidence interval; FNB, fine-needle biopsy; OR, odd ratio.
**Table 3.** Characteristic of Study Lesions after Propensity Score Matching (n=482).

| Location            | Menghini needle (n=241) | Franseen needle (n=241) | p-value |
|---------------------|-------------------------|-------------------------|---------|
| Pancreas            | 197 (81.7%)             | 193 (80.1%)             | 0.91    |
| Head                | 79 (40.1%)              | 83 (43.0%)              |         |
| Body and tail       | 118 (59.9%)             | 110 (57.0%)             |         |
| Lymph node          | 20 (8.3%)               | 21 (8.7%)               |         |
| Submucosal tumor    | 13 (5.4%)               | 17 (7.1%)               |         |
| Esophagus           | 2 (1.5%)                | 1 (5.9%)                |         |
| Stomach             | 11 (4.6%)               | 16 (9.1%)               |         |
| Others              | 11 (4.6%)               | 10 (4.1%)               |         |

| Access route, n (%)| Franseen (events/lesions) | Menghini (events/lesions) | p-value |
|-------------------|---------------------------|---------------------------|---------|
| Transgastric      | 140/155                   | 130/141                   | 1.02 (0.93-1.12) | 0.83   |
| Transduodenal     | 66/77                     | 75/90                     | 1.24 (1.00-1.52) | 0.11   |
| Others            | 8/9                       | 10/11                     | 1.13 (0.89-1.34) | 0.47   |

| Size of lesion (mm), median (range) | Franseen (events/lesions) | Menghini (events/lesions) | p-value |
|------------------------------------|---------------------------|---------------------------|---------|
| Large lesion                       | 142/154                   | 164/183                   | 0.97 (0.85-1.11) | 1.00   |
| Small lesion                       | 72/87                     | 51/58                     | 1.06 (0.93-1.22) | 0.48   |

| Diagnostic yield                  | Franseen                  | Menghini                  | p-value |
|-----------------------------------|---------------------------|---------------------------|---------|
| Cytology only                     | 93.4%                     | 88.8%                     | 0.11    |
| Histology only                    | 89.2%                     | 88.8%                     | 1.00    |
| Histology plus cytology           | 97.5%                     | 94.2%                     | 0.11    |

*a* Including intraperitoneal nodule 4, liver 3, adrenal grand 1, mediastinum 1, and gall bladder 2.

*b* Including intraperitoneal nodule 8, liver 1, and mediastinum 1.

*c* Transesophageal 10.

*d* Transesophageal 4, through the jejunum 3, and through the rectum 2.

**Fig. 3.** Forest plot for subgroup analysis. Large lesion, >2 cm; Small lesion, ≤2 cm. CI, confidence interval; OR, odds ratio.
**DISCUSSION**

We conducted a large, retrospective comparison of two FNB needles in 690 lesions. The puncture could be performed in almost all cases, and it was observed that both needles were easy to handle, even in cases of transduodenal access. The tissue acquisition rate was 98.4%, the diagnosis rate of histology alone was 88.8%, and the combined diagnosis rate of histology and cytology was 95.7%, which were very good results. This high diagnostic yield could be obtained with a median of only two punctures using ROSE. The AE rate in this study was 1.5%, which is similar to those mentioned in previous studies of EUS-FNA. Therefore, EUS-FNB can be considered as a safe procedure. Multivariate analysis showed that transduodenal access and small lesions were negative predictive factors for the diagnostic accuracy of histology, but the combined diagnostic rates of histology and cytology of each needle were relatively high (transduodenal access and small lesion, 94.9% and 91.1%, respectively). After performing propensity score matching to adjust for background factors of these two needles, no clear difference was observed in the rate of tissue collection for histological diagnosis or the diagnostic yields of both needles. There have been no reports comparing the performance of these two FNB needles after adjusting for background factors, in such a large number of cases. In the subgroup analysis, there was no significant difference between the two needles. However, in case of lymph node lesions, M needle was observed to have better results (OR, 1.24; 95% CI, 1.00–1.52; \( p = 0.11 \)).

In this study, both the FNB needles had high diagnostic yields for obtaining a histological diagnosis. There are few reports on the diagnostic rate of FNB needles (include FNA needles in some cases) in small lesions, which is reported to be around 71%–82%. However, it is not clear if this can be considered as the diagnostic rate for histology alone. In this study, 83.9% of the histological diagnoses and 91.1% of the combined diagnoses with histology and cytology were obtained, even for small lesions (≤2 cm), which can be considered as promising results.

There are only a few reports comparing M needles with F needles: one retrospective study and one prospective study. In the retrospective study, FNB was performed for 34 lesions with 20 G M needle, and 34 lesions with 22 G F needle. The histological diagnosis rates with these two needles were equivalent (82% with M needle and 97% with F needle, \( p = 0.10 \)). The same group reported a prospective study at UEGW 2019, with 60 lesions punctured by both 20 G M and 22 G F needles. A histological diagnosis was achieved in 68% of the samples obtained with M needle and in 88% with F needle (\( p = 0.02 \)). In addition, the authors reported that F needle was able to acquire longer tissue fragments than M needle. However, these studies were limited to a small number of pancreatic lesions; therefore, caution is required in the interpretation of their results. Regarding the length of the tissue fragment, the thickness of the needle is different between the 20 G and 22 G needles, and it is unknown whether the amount of collected tissue can be accurately evaluated.

In this study, propensity score matching was performed to adjust for background factors between the two groups. Even after adjustment, this was a large-scale study of 482 lesions, and there have been limited comparative reports on EUS-guided tissue acquisitions of this scale to date. As a result of propensity score matching, no clear differences were observed in the tissue collection rate and the diagnostic ability between M and F needles. Subgroup analysis also showed no clear difference between needles, but M needles tended to be slightly better for lymph node lesions. Since many lymph node lesions are soft lesions, the tissue can be easily cut by the forward bevel in the side hole, and the needle is as large as 20 G, so we speculate that M needle could potentially collect larger tissue samples. On the other hand, it was reported that the maneuverability of large-diameter needles deteriorates due to the bending of the scope, and it was expected that the diagnostic ability of 20 G M needle might decrease in cases of transduodenal access or pancreatic head lesions. However, no significant difference was observed between the two groups for either the pancreatic head lesions or transduodenal access in our study.

There are some limitations in this study. First, this is a retrospective study of a single center. However, this study includes a large number of cases extracted from a prospectively accumulated database, and an analysis after propensity score matching was also performed with a large number of cases. Second, not all FNB needles available in the world were evaluated in this study. The FNB needle with a fork tip is widely used. However, this needle has not yet been introduced in Japan. There are some reports comparing Fork-tip needle and F needle, yet the superiority of one over the other in terms of diagnostic accuracy remains controversial. Therefore, it is necessary to compare these three needles in future studies. Third, the amounts of tissue collected cannot be compared objectively. Moreover, it is necessary to further study whether the sample enables the genetic panel test that is currently attracting attention. Fourth, in the forest plot, there were few tumors other than pancreatic lesions; therefore, the location may have affected the results. Finally, not only experts but also trainees were included as operators. While there was a higher tendency for experts to be involved in the M group after propensity score matching, it did not influence the histological diagnostic accuracy in multi-
variate analysis. This is similar to what is encountered in actual clinical practice and this result can thus be generalized.

In conclusion, we conducted a comparative study on the efficacy and safety of two FNB needles in a large number of cases. Unlike previous reports, both M and F needles proved to have good diagnostic abilities and safety, with no clear difference in the performance of these two needles.

Conflicts of Interest
The authors have no potential conflicts of interest.

Funding
None.

Author Contributions
Conceptualization: Takafumi Mie, Takashi Sasaki, Ryo Kanata, Masato Matsuyama, Naoki Sasahira
Data curation: TM, RK, Takaaki Furukawa, Tsuyoshi Takeda, Akiyoshi Kasuga
Formal analysis: TM, TS, RK, TT
Investigation: TM, RK, TF, TT, AK
Methodology: TM, TS, RK, TT
Project administration: Masato Ozaka, NS
Supervision: MO, NS
Writing-original draft: TM
Writing-review & editing: TS, TT, NS

ORCID
Takafumi Mie: https://orcid.org/0000-0002-7561-5558
Takashi Sasaki: https://orcid.org/0000-0001-7109-9835
Ryo Kanata: https://orcid.org/0000-0001-7544-8609
Takaaki Furukawa: https://orcid.org/0000-0002-9746-6776
Tsuyoshi Takeda: https://orcid.org/0000-0002-0786-8166
Akiyoshi Kasuga: https://orcid.org/0000-0002-2334-1135
Masato Matsuyama: https://orcid.org/0000-0003-3604-1624
Masato Ozaka: https://orcid.org/0000-0002-5666-1970
Naoki Sasahira: https://orcid.org/0000-0002-0672-7214

REFERENCES

1. Ryozawa S, Kitoh H, Gondo T, et al. Usefulness of endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of pancreatic cancer. J Gastroenterol 2005;40:907-911.
2. Yasuda I, Tsurumi H, Omar S, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of unknown origin. Endoscopy 2006;38:919-924.
3. Inoue T, Okumura F, Fano H, et al. Impact of endoscopic ultrasound-guided fine-needle biopsy on the diagnosis of subepithelial tumors: a propensity score-matching analysis. Dig Endosc 2019;31:156-163.
4. Kamata K, Kitano M, Yasukawa S, et al. Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial. Endoscopy 2016;48:632-638.
5. Iwashita T, Yasuda I, Doi S, et al. Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis. Clin Gastroenterol Hepatol 2012;10:316-322.
6. Lee YN, Moon JH, Kim HK, et al. Core biopsy needle versus standard aspiration needle for endoscopic ultrasound-guided sampling of solid pancreatic masses: a randomized parallel-group study. Endoscopy 2014;46:1056-1062.
7. Lee BS, Cho CM, Jung MK, Jung JS, Bae HJ. Comparison of histologic core portions acquired from a core biopsy needle and a conventional needle in solid mass lesions: a prospective randomized trial. Gut Liver 2017;11:559-566.
8. Sterlacci W, Soulou AD, Veits L, et al. 22-gauge core vs 22-gauge aspiration needle for endoscopic ultrasound-guided sampling of abdominal masses. World J Gastroenterol 2016;22:8820-8830.
9. Fuji S, Ishiwatari H, Sasaki K, et al. Comparison of the diagnostic yield of the standard 22-gauge needle and the new 20-gauge forward-bevel core biopsy needle for endoscopic ultrasound-guided tissue acquisition from pancreatic lesions. Gut Liver 2019;13:349-355.
10. Nishioaka N, Ogura T, Kurisu Y, et al. Prospective histological evaluation of a 20G core trap with a forward-cutting bevel needle for EUS-FNA of pancreatic lesions. Surg Endosc 2018;32:4125-4131.
11. van Riet PA, Laghi A, Attili F, et al. A multicenter randomized trial comparing a 25-gauge EUS fine-needle aspiration device with a 20-gauge EUS fine-needle biopsy device. Gastrointest Endosc 2019;89:329-339.
12. Fabbri C, Formelli A, Fuccio L, et al. High diagnostic adequacy and accuracy of the new 20G procore needle for EUS-guided tissue acquisition: results of a large multicentre retrospective study. Endosc Ultrasound 2019;8:261-268.
13. Armellini E, Manfrin E, Trisolini E, et al. Histologic retrieval rate of a newly designed side-bevelled 20G needle for EUS-guided tissue acquisition of solid pancreatic lesions. United European Gastroenterol J 2019;7:96-104.
14. Mita N, Iwashita T, Uemura S, et al. Endoscopic ultrasound-guided fine-needle biopsy using 22-gauge Franseen needle for the histological diagnosis of solid lesions: a multicenter prospective pilot study. Dig Dis Sci 2020;65:1155-1163.
15. Bang JY, Hebert-Magee S, Hasan MK, Nanavateethan U, Hawes R, Varadarajulu S. Endoscopic ultrasonography-guided biopsy using a Franseen needle design: initial assessment. Dig Endosc 2017;29:338-346.
16. Kandel P, Tranesh G, Nasser A, et al. EUS-guided fine-needle biopsy sampling using a novel fork-tip needle: a case-control study. Gastrointest Endosc 2016;84:1034-1039.
17. Matsuho J, Ogura T, Kurisu Y, et al. Prospective comparison study of franseen needle and standard needle use for pancreatic lesions under EUS guidance. Endosc Ultrasound 2019;8:412-417.
18. Mukai S, Itoi T, Yamaguchi H, et al. A retrospective histological comparison of EUS-guided fine-needle biopsy using a novel franseen needle and a conventional end-cut type needle. Endosc Ultrasound 2019;8:50-57.
19. El H, Wu H, Reuss S, et al. Prospective assessment of the performance of a new fine-needle biopsy device for EUS-FNB: sampling of solid lesions. Clin Endosc 2018;51:576-583.
20. Renelus BD, Jamorabo DS, Boston I, Briggs WM, Poneromas J. Endoscopic ultrasound-guided fine-needle biopsy needles provide higher diagnostic yield compared to endoscopic ultrasound-guided fine-needle aspiration needles when sampling solid pancreatic lesions: a meta-analysis. Clin Endosc 2021;54:261-268.
21. Gleeson FC, Levy MJ, Roden AC, et al. EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy. Endosc Int Open 2018;6:E1278-E1282.
22. Muniraj T, Aslanian HR. New developments in endoscopic ultrasound tissue acquisition. Gastrointest Endosc Clin N Am 2017;27:585-599.
23. Conti CB, Cerretti F, Grassia R. Endoscopic ultrasound-guided sampling of solid pancreatic masses: the fine-needle aspiration or fine-needle biopsy dilemma. Is the best needle yet to come? World J Gastrointest Endosc 2019;11:454-471.
24. Bang JY, Magee SH, Ramesh J, Trevino JM, Varadarajulu S. Randomized trial comparing fanning with standard technique for endoscopic ultra-
sound-guided fine-needle aspiration of solid pancreatic mass lesions. Endoscopy 2013;45:445-450.
25. Nakai Y, Isayama H, Chang KJ, et al. Slow pull versus suction in endoscopic ultrasound-guided fine-needle aspiration of pancreatic solid masses. Dig Dis Sci 2014;59:1578-1585.
26. Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010;71:446-454.
27. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452-458.
28. Sasaki T, Kanata R, Sasahira N. Needle fracture during endoscopic ultrasound-guided fine-needle aspiration using a needle with a side hole. Endosc Int Open 2018;6:E553-E557.
29. Yoshinaga S, Itoi T, Yamato K, et al. Safety and efficacy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic masses: a prospective multicenter study. Dig Endosc 2020;32:114-126.
30. Hwang CY, Lee SS, Song TJ, et al. Endoscopic ultrasound guided fine-needle aspiration biopsy in diagnosis of pancreatic and peripancreatic lesions: a single center experience in Korea. Gut Liver 2009;3:116-121.
31. Fabbri C, Luigiano C, Maimone A, et al. Endoscopic ultrasound-guided fine-needle biopsy of small solid pancreatic lesions using a 22-gauge needle with side fenestration. Surg Endosc 2015;29:1586-1590.
32. Karsenti D, Tharris G, Zeitoun JD, et al. Comparison of 20-gauge Pro-core and 22-gauge Acquire needles for EUS-FNB of solid pancreatic masses: an observational study. Scand J Gastroenterol 2019;54:499-505.
33. Karsenti D, Palazzo L, Perrot B, et al. Multicenter randomized controlled trial (RCT) comparing the histological material quantity obtained by endoscopic ultrasound fine-needle biopsy (EUS-FNB) of pancreatic masses with two “biopsy” needles: the 20-gauge Procore (Cook) and the 22-gauge Acquire (Boston Scientific). United European Gastroenterol J 2019;7(Suppl):28.
34. Bang JY, Kirtane S, Krall K, et al. In memoriam: fine-needle aspiration, birth: fine-needle biopsy: the changing trend in endoscopic ultrasound-guided tissue acquisition. Dig Endosc 2019;31:197-202.
35. Karadsheh Z, Al-Haddad M. Endoscopic ultrasound-guided fine-needle aspiration needles: which one and in what situation? Gastrointest Endosc Clin N Am 2014;24:109-124.
36. Vilmann P, Seicean A, Săftoiu A. Tips to overcome technical challenges in EUS-guided tissue acquisition. Gastrointest Endosc Clin N Am 2014;24:109-124.
37. Abdelfatah MM, Grimm IS, Gangarosa LM, Baron TH. Cohort study comparing the diagnostic yields of 2 different EUS fine-needle biopsy needles. Gastrointest Endosc 2018;87:495-500.
38. Bang JY, Hebert-Magee S, Naveenethan U, Hasan MK, Hawes R, Varadaraju S. Randomized trial comparing the Franseen and Fork-tip needles for EUS-guided fine-needle biopsy sampling of solid pancreatic mass lesions. Gastrointest Endosc 2018;87:1432-1438.